Objective: This double-blind, parallel, multicentre study investigated the effect of migraine on absorption of oral sumatriptan (25, 50 and 100mg) compared with placebo.
Design: Patients received sumatriptan or placebo in the clinic during an acute migraine and at least 7 days later, when pain-free. Pharmacokinetic and efficacy (n = 192) and safety (n = 259) parameters were assessed for 4 hours after administration of study medication.
Results: Absorption of sumatriptan from 50 and 100mg tablets was not significantly different between the migraine and pain-free periods. There was however a statistically significant decrease (approximately 23%) and delay (35 minutes) in absorption of sumatriptan from the 25mg tablet during a migraine compared with the pain-free period. Sumatriptan pharmacokinetics exhibited dose proportionality during the migraine and pain-free periods. All doses of sumatriptan were significantly superior to placebo in reducing headache pain. Adverse events were comparable among the sumatriptan groups and placebo group.
Conclusions: Absorption of sumatriptan, administered at therapeutic doses, was not statistically significantly impaired during migraine versus the pain-free state. These data suggest that coadministration of drugs that improve the absorption of sumatriptan is not necessary during sumatriptan treatment.
Connor HE, Feniuk W, Humphrey PPA. Characterization of 5-HT receptors mediating contraction of canine and primate basilar artery by use of GR43175, a selective 5-HT1-like receptor agonist. Br J Pharmacol 1989; 96: 379–87PubMedCrossRefGoogle Scholar
Humphrey PPA, Feniuk W, Perren MJ, et al. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 1989; 9 Suppl. 9: 23–33PubMedGoogle Scholar
Parsons AA, Whalley ET. Characterization of the 5-hydroxy-tryptamine receptor which mediates contraction of the human isolated basilar artery. Cephalalgia 1989; 9 Suppl. 9: 47–51PubMedGoogle Scholar
Van Es NM, Bruning TA, Camps J, et al. Assessment of peripheral vascular effects of antimigraine drugs in humans. Cephalalgia 1995; 15(4): 288–91CrossRefGoogle Scholar
Dechant KL, Clissold SP. Sumatriptan: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1992; 43(5): 776–98PubMedCrossRefGoogle Scholar
Friberg L, Olesen J, Iversen HK, et al. Migraine pain associated with middle cerebral artery dilation: reversal by sumatriptan. Lancet 1991; 338: 13–7PubMedCrossRefGoogle Scholar
Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992; 13:307–12PubMedCrossRefGoogle Scholar
Goadsby PJ, Hoskin KL. Serotonin inhibits trigeminal nucleus activity evoked by craniovascular stimulation through a 5HT1b/1d receptor: a central action in migraine? Ann Neurol 1998; 43(6): 711–8PubMedCrossRefGoogle Scholar
Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990; 99: 202–6PubMedCrossRefGoogle Scholar
Pearce JMS. Sumatriptan: efficacy and contribution to migraine mechanisms. J Neurol Neurosurg Psychiatry 1992; 55: 1103–5PubMedCrossRefGoogle Scholar
Plosker GL, McTavish D. Sumatriptan: a reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Drugs 1994; 47(4): 622–51PubMedCrossRefGoogle Scholar
May A, Shepheard SL, Knorr M, et al. Retinal plasma extravasation in animals but not humans: implications for the pathophysiology of migraine. Brain 1998; 121: 1231–7PubMedCrossRefGoogle Scholar
Cady RK, Wendt JK, Kirchner JR, et al. Treatment of acute migraine with subcutaneous sumatriptan. JAMA 1991; 265: 2831–5PubMedCrossRefGoogle Scholar
The Oral Sumatriptan Dose-Defining Study Group. Sumatriptan — an oral dose defining study. Eur Neurol 1991; 31: 300–5CrossRefGoogle Scholar
Carpay HA, Matthijsse P, Steinbuch M, et al. Oral and subcutaneous sumatriptan in the acute treatment of migraine: an open randomized cross-over study. Cephalalgia 1997; 17(5): 591–5PubMedCrossRefGoogle Scholar
Kelly AM, Ardagh M, Curry C, et al. Intravenous chlorpromazine versus intramuscular sumatriptan for acute migraine. J Accid Emerg Med 1997; 14(4): 209–11PubMedCrossRefGoogle Scholar
Eckborn K, Monstad I, Prusinski A, et al. Subcutaneous sumatriptan in the acute treatment of cluster headache: a dose comparison study. Acta Neurol Scand 1993; 88: 63–9Google Scholar
Ryan R, Elkind A, Baker CC, et al. Sumatriptan nasal spray for the acute treatment of migraine. Results of two clinical studies. Neurology 1997; 49(5): 1225–30PubMedCrossRefGoogle Scholar
Ross-Lee LM, Eadie MJ, Heazlewood V, et al. Aspirin pharmacokinetics in migraine. The effect of metoclopramide. Eur J Clin Pharmacol 1983; 24: 777–85PubMedCrossRefGoogle Scholar
Tokola RA, Neuvonen PJ. Effect of migraine attacks on paracetamol absorption. Br J Clin Pharmacol 1984; 18: 867–71PubMedCrossRefGoogle Scholar
Tokola RA. The effect of metoclopramide and prochlorperazine on the absorption of effervescent paracetamol in migraine. Cephalalgia 1988; 8: 139–47PubMedCrossRefGoogle Scholar
Tokola RA, Neuvonen PJ. Effects of migraine attack and metoclopramide on the absorption of tolfenamic acid. Br J Clin Pharmacol 1984; 17: 67–75PubMedCrossRefGoogle Scholar
Pini LA, Bertolotti M, Trenti T, et al. Disposition of naproxen after oral administration during and between migraine attacks. Headache 1993; 33(4): 191–4PubMedCrossRefGoogle Scholar
Houghton LA, Fowler P, Keene ON, et al. Effect of sumatriptan, a new selective 5HT-1-like agonist, on gastric emptying in man. Aliment Pharmacol Ther 1992; 6(6): 685–91PubMedCrossRefGoogle Scholar
Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8 Suppl. 7: 19–28Google Scholar
Busch MA, Plachetka JR, Donn KH, et al. Evaluation of the pharmacokinetics and safety of ascending single oral doses of GR43175 administered to healthy male volunteers. Cephalalgia 1989; 9 Suppl. 10: 414–5Google Scholar
Pini L-A, Bertolotti M, Bergonzini G, et al. Pharmacokinetics of tiaprofenic acid after oral administration in fasting patients during and between migraine attacks. Headache 1990; 30: 672–5PubMedCrossRefGoogle Scholar
Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol 1991; 31: 291–4PubMedCrossRefGoogle Scholar
Fowler PA, Lacey LF. The effect of food on the pharmacokinetic profile of sumatriptan. Abstract XVth World Congress of Neurology, Vancouver, September 5–10, 1993Google Scholar